Moclobemide
| Evidence Level: L2 | Predicted Indications: 2 |
Table of Contents
Moclobemide: From Anxiety Disorder to Agoraphobia
One-Sentence Summary
Moclobemide is a reversible inhibitor of monoamine oxidase A (RIMA), originally used for anxiety disorder, neurotic disorder and dysthymic disorder. The TxGNN model predicts it may be effective for agoraphobia, with no registered clinical trials but 10 publications (including 2 randomised controlled trials in panic disorder with or without agoraphobia) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Anxiety disorder, neurotic disorder, dysthymic disorder (the Canadian licence records contain no indication text) |
| Predicted New Indication | Agoraphobia |
| TxGNN Prediction Score | 0.9943 |
| Evidence Level | L2 |
| Canada Market Status | Marketed (marketed DINs: 4 of 5; dormant: 1) |
| Number of DINs | 5 (marketed: 4) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Moclobemide selectively and reversibly inhibits monoamine oxidase A (MAO-A). This slows the breakdown of serotonin, norepinephrine and dopamine and raises their levels in the synapse. Detailed mechanism data were not available in the compiled record. The mechanism described here comes from the pharmacology target data (MAO-A and MAO-B) and general pharmacology.
Agoraphobia usually occurs together with panic disorder and belongs to the same family of anxiety disorders as moclobemide’s existing indications. Monoaminergic drugs are already used for panic disorder and social anxiety. The published studies below tested moclobemide in panic disorder with or without agoraphobia and in social phobia. This biological and clinical closeness fits the very high TxGNN score.
The evidence is still indirect. The trials studied panic disorder with agoraphobia, not agoraphobia as a stand-alone condition.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10448444 | 1999 | RCT | Br J Psychiatry | Placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia |
| 10361962 | 1999 | RCT | Eur Arch Psychiatry Clin Neurosci | Moclobemide 450 mg/day vs clomipramine 150 mg/day in panic disorder with and without agoraphobia (135 patients, double-blind) |
| 28867934 | 2017 | Review | Dialogues Clin Neurosci | Guideline-based review of treatments for anxiety disorders, including panic disorder/agoraphobia |
| 32002937 | 2020 | Review | Adv Exp Med Biol | Psychopharmacological recommendations for anxiety disorders based on guidelines and meta-analyses |
| 7717094 | 1995 | Review | Acta Psychiatr Scand Suppl | Review of reversible MAO-A inhibitors (including moclobemide) in mental and other disorders |
| 8313401 | 1993 | Review | Clin Neuropharmacol | Reversible MAO-A inhibitors in panic disorder; they are better tolerated and need no dietary restrictions |
| 12006898 | 2002 | Review | J Clin Psychopharmacol | Model of therapeutic response in panic disorder using moclobemide data |
| 16850261 | 2006 | Other | Metab Brain Dis | Citalopram vs moclobemide effects on resting brain perfusion in social anxiety disorder |
| 7954487 | 1994 | Other | Clin Neuropharmacol | Open pilot study of moclobemide in 35 patients with social phobia; improvement in fear and avoidance |
| 7892341 | 1995 | Case report | Psychiatr Prax | Treatment-refractory panic disorder with agoraphobia that remitted with imipramine, moclobemide and behavioural therapy |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 00899356 | MANERIX | Not specified | Not specified |
| 02166747 | MANERIX | Not specified | Not specified |
| 02240456 | MOCLOBEMIDE | Not specified | Not specified |
| 02232150 | MOCLOBEMIDE | Not specified | Not specified |
| 02232148 | MOCLOBEMIDE | Not specified | Not specified |
Safety Considerations
- Drug Interactions: The compiled data list only pharmacological targets, namely monoamine oxidase A (MAOA) and monoamine oxidase B (MAOB). They do not list specific interacting drugs.
For warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Two randomised controlled trials in panic disorder with or without agoraphobia, plus several reviews, support moclobemide in this area. The drug is already marketed in Canada under 5 DINs for related anxiety disorders. However, no registered trials target agoraphobia itself, and the available safety data are incomplete. The evidence is therefore best treated as a well-supported research question, not a ready-to-use indication.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications, which are currently missing and block safety screening
- Detailed mechanism of action data from DrugBank
- Trial data specific to agoraphobia, or a pooled analysis of the existing panic disorder with agoraphobia trials
- A review of the full text of the two RCTs to confirm outcomes and the agoraphobia subgroup
- Interaction and dietary guidance for MAO inhibitors from the package insert
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.